Imaging Biomarkers as Predictors for Breast Cancer Death

Table 1

Distribution of age, mammographic appearance, histologic tumor distribution, and conventional tumor attributes in two study cohorts.

	Women diagnosed between 1996-1998		Women diagnosed between 2006-2010
	Number	Percentage (%)	Number	Percentage (%)
Age, years
<40	13	2.61	21	2.48
40–49	67	13.45	117	13.80
50–59	113	22.69	169	19.93
60–69	113	22.69	254	29.95
70–79	107	21.49	171	20.17
80+	85	17.07	116	13.68
Mammographic appearance
Stellate	212	43.89	371	46.55
Circular	161	33.33	235	29.49
Powdery	15	3.11	12	1.51
Casting	32	6.63	46	5.77
Crushed stone-like	40	8.28	94	11.79
Architectural distortion	23	4.76	39	4.89
NK	15		51
Basal type
Non-basal phenotype	401	90.11	634	88.80
Basal phenotype	44	9.89	80	11.20
NK	53		134
Histologic tumor distribution
Unifocal	299	65.28	458	55.25
Multifocal	115	25.11	301	36.31
Diffuse	44	9.61	70	8.44
NK	40		19
Tumor size (mm)
1–9	85	18.52	152	18.51
10–14	92	20.04	192	23.39
15–19	95	20.70	178	21.68
20–29	114	24.84	187	22.78
30–49	58	12.64	88	10.72
50+	15	3.27	24	2.92
NK	39		27
Histologic malignancy grade
I/II	341	74.13	627	76.84
III	119	25.87	189	23.16
NK	38		32
Lymph node involvement
Negative	331	72.43	513	61.51
Positive	126	27.57	321	38.49
NK	41		14
Surgery type
Breast conserving surgery	252	54.55	309	50.32
Mastectomy	210	45.45	305	49.68
NK	36		234
Radiotherapy
No	195	39.47	206	34.39
Yes	299	60.53	393	65.61
NK	4		249
Chemotherapy
No	408	82.59	382	63.88
Yes	86	17.41	216	36.12
NK	4		250
Hormone therapy
No	374	75.71	207	34.62
Yes	120	24.29	391	65.38
NK	4		250

NK, not known.